Schizophrenia: Facts, DSM-5 Criteria and Treatment

Schizophrenia’s intricate dance with mood disorders is noteworthy. Coexistence with Major Depressive Disorder (MDD) is possible if mood symptoms are present for less than half the time. However, if mood symptoms predominate, the diagnosis leans towards Schizoaffective Disorder (SCAD).

First episode psychosis, a crucial juncture, often occurs between ages 18 and 24 for men and 25 to 35 for women. For women, a distinctive bimodal distribution emerges, revealing a secondary peak between ages 50 to 54. Interestingly, late onset schizophrenia after 60 years of age can occur, a phenomenon that can respond favorably to antipsychotic treatment and may necessitates only half the typical dosage. Late-onset schizophrenia might also serve as a prodrome of dementia.

In the United States, the lifetime prevalence of schizophrenia stands at 1%. This condition is notably heritable, with genetics accounting for approximately 80% of its liability. Prognosis varies; better outcomes are associated with positive symptoms, female sex, absence of family history, a positive family history of mood disorders, sudden onset of symptoms, clear precipitating factors, high premorbid functioning, and robust social support.

Insomnia, affecting 50% of individuals with psychosis, emerges as an intriguing predictor. It can foreshadow the onset of psychotic episodes, highlighting the importance of addressing sleep disturbances as a strategy for early intervention.

Schizophrenia can lead to periods of crisis requiring hospitalization for effective management. Treating this complex disorder involves targeted interventions to alleviate distressing symptoms. Antipsychotic medications are the cornerstone of treatment, aiming to address hallucinations, delusions, and disorganized thinking. Long-acting injectable antipsychotics such as Invega (paliperidone), Abilify Maintena (aripiprazole), and haldol decanoate have emerged as valuable options, offering sustained release and improved adherence.

These injectables provide convenience and stability, reducing the need for frequent dosing.

As we unveil avenues for diagnosis, treatment, and support, we move closer to providing holistic care and fostering an empathetic environment for individuals confronting the challenges of schizophrenia.